Daiichi snaps up Japanese rights to CVD stem-cell therapy – BioPharma Dive
BioPharma-Reporter.com |
Daiichi snaps up Japanese rights to CVD stem–cell therapy
BioPharma Dive Japanese drugmaker Daiichi Sankyo has bought rights to market U.K.-based Cell Therapy's regenerative heart treatment in Japan, boosting the profile of the stem cell therapy company. Cell Therapy, founded by Nobel Prize-winner Martin Evans, will receive … Daiichi Sankyo licenses off-the-shelf regenerative heart cell therapy from CTL Cell Therapy licenses heart failure therapy in Japan Cell Therapy Ltd's CEO Ajan Reginald talks to TPL's Katie Osborne |
